Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA).

Mupirocin has become the topical agent of choice for the elimination of methicillin-resistant Staphylococcus aureus (MRSA) carriage. The increased use of this antibiotic has been followed by reports of outbreaks due to MRSA with both low- and high-level resistance. Whilst low-level resistance is becoming more widespread, it is unlikely to have a major impact upon current practice. High-level resistance is plasmid borne, and although uncommon, can lead to problems with elimination especially in an outbreak situation. Alternatives are available but uncertainty exists as to their efficacy and safety. Any strategy to limit the increase of mupirocin resistance in MRSA should emphasize the importance of controlled antibiotic use both for mupirocin and other agents.

[1]  J. Gilbart,et al.  High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases , 1993, Antimicrobial Agents and Chemotherapy.

[2]  V. Yu,et al.  Staphylococcus aureus nasal carriage in hemodialysis patients. Its role in infection and approaches to prophylaxis. , 1989, Archives of internal medicine.

[3]  I. Phillips,et al.  Mupirocin resistance in coagulase-negative staphylococci. , 1993, Journal of medical microbiology.

[4]  D. Flournoy,et al.  Mupirocin resistance in methicillin-resistant Staphylococcus aureus from a veterans hospital. , 1993, Chemotherapy.

[5]  K. Crossley,et al.  An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. II. Epidemiologic studies. , 1979, The Journal of infectious diseases.

[6]  B. Slocombe,et al.  The antimicrobial activity of mupirocin--an update on resistance. , 1991, The Journal of hospital infection.

[7]  M. Rahman,et al.  An investigation of plasmids from Staphylococcus aureus that mediate resistance to mupirocin and tetracycline. , 1994, Microbiology.

[8]  R. Hill,et al.  In-vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus. , 1985, The Journal of antimicrobial chemotherapy.

[9]  R. Hill,et al.  Minimal dose requirements for nasal mupirocin and its role in the control of epidemic MRSA. , 1991, The Journal of hospital infection.

[10]  H. Haruyama,et al.  Thiomarinol, a new hybrid antimicrobial antibiotic produced by a marine bacterium. Fermentation, isolation, structure, and antimicrobial activity. , 1993, The Journal of antibiotics.

[11]  M. Terpenning,et al.  Detection and characterization of mupirocin resistance in Staphylococcus aureus , 1993, Antimicrobial Agents and Chemotherapy.

[12]  K. Barrow,et al.  Pseudomonic Acid: an Antibiotic produced by Pseudomonas fluorescens , 1971, Nature.

[13]  K. Crossley,et al.  An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. I. Clinical studies. , 1979, The Journal of infectious diseases.

[14]  R. Hill,et al.  Elimination of nasal carriage of Staphylococcus aureus with mupirocin ('pseudomonic acid')--a controlled trial. , 1986, The Journal of antimicrobial chemotherapy.

[15]  E. Jenner,et al.  NASAL CARRIAGE OF GENTAMICIN AND METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATED WITH TOPICAL PSEUDOMONIC ACID , 1983, The Lancet.

[16]  G. Duckworth.  Revised guidelines for the control of epidemic methicillin-resistant Staphylococcus aureus. Report of a combined working party of the Hospital Infection Society and British Society for Antimicrobial Chemotherapy. , 1990, The Journal of hospital infection.

[17]  R. Marples,et al.  A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16) , 1995, The Journal of hospital infection.

[18]  R. Hill,et al.  Mupirocin ('pseudomonic acid')--a promising new topical antimicrobial agent. , 1987, The Journal of antimicrobial chemotherapy.

[19]  R. Hill,et al.  The carrier state: methicillin-resistant Staphylococcus aureus. , 1986, The Journal of antimicrobial chemotherapy.

[20]  S J Dawson,et al.  Mupirocin-resistant MRSA. , 1994, The Journal of hospital infection.

[21]  B. Cookson,et al.  Mupirocin-resistant Staphylococcus aureus , 1987, The Lancet.

[22]  B. Cookson.  Mupirocin resistance in staphylococci. , 1990, The Journal of antimicrobial chemotherapy.

[23]  W. Grubb,et al.  Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus in Western Australia. , 1994, The Journal of hospital infection.

[24]  J. Hughes,et al.  On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus. , 1978, The Journal of antibiotics.

[25]  J. Patterson,et al.  Mupirocin resistance among consecutive isolates of oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus at a university hospital , 1994, Antimicrobial Agents and Chemotherapy.

[26]  Redhead Rj,et al.  The efficacy of calcium mupirocin in the eradication of nasal Staphylococcus aureus carriage. , 1991 .

[27]  J. Hamilton-miller,et al.  Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against methicillin-resistant Staphylococcus aureus. , 1992, The Journal of antimicrobial chemotherapy.

[28]  W. Noble,et al.  Cloning of the gene conferring resistance to mupirocin in Staphylococcus aureus. , 1991, FEMS microbiology letters.

[29]  C. Goodwin,et al.  Control of methicillin-resistant Staphylococcus aureus (MRSA) in an Australian metropolitan teaching hospital complex. , 1985, The Medical journal of Australia.

[30]  M. Rahman,et al.  Probes for the study of mupirocin resistance in staphylococci. , 1993, Journal of medical microbiology.

[31]  I. Hudson,et al.  The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience. , 1994, The Journal of hospital infection.

[32]  B. Cookson,et al.  Prevalence of mupirocin resistance in Staphylococcus aureus. , 1995, The Journal of hospital infection.

[33]  M. Shields,et al.  An outbreak of infection with a methicillin-resistant Staphylococcus aureus in a special care baby unit: value of topical mupirocin and of traditional methods of infection control. , 1987, The Journal of hospital infection.

[34]  M. Vilardell,et al.  von Willebrand factor activity in primary and in scleroderma-associated Raynaud's phenomenon , 1990, The Lancet.

[35]  K. Dyke,et al.  Molecular characterization of the gene encoding high-level mupirocin resistance in Staphylococcus aureus J2870 , 1994, Antimicrobial Agents and Chemotherapy.

[36]  R. Hill,et al.  Elimination of nasal carriage of methicillin-resistant Staphylococcus aureus with mupirocin during a hospital outbreak. , 1988, The Journal of antimicrobial chemotherapy.

[37]  J. Williams,et al.  Methicillin-resistant Staphylococcus aureus: report of an outbreak in a London teaching hospital. , 1988, The Journal of hospital infection.